Survival Outcomes for Yttrium-90 Transarterial Radioembolization With and Without Sorafenib for Unresectable Hepatocellular Carcinoma Patients

PURPOSE: To assess the overall survival (OS) and progression-free survival (PFS) of unresectable hepatocellular carcinoma (HCC) patients undergoing yttrium-90 glass–microsphere transarterial radioembolization (TARE) with and without concurrent sorafenib. METHODS: OS and PFS were analyzed in 55 patie...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Hepatocell Carcinoma
Asıl Yazarlar: Teyateeti, Ajalaya, Mahvash, Armeen, Long, James P, Abdelsalam, Mohamed E, Avritscher, Rony, Chasen, Beth, Kaseb, Ahmed O, Kuban, Joshua D, Murthy, Ravi, Odisio, Bruno C, Teyateeti, Achiraya, Macapinlac, Homer A, Kappadath, S Cheenu
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Dove 2020
Konular:
Original Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7500841/
https://ncbi.nlm.nih.gov/pubmed/32984089
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JHC.S248314
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller